当前位置：
X-MOL 学术
›
Eur. Urol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Re: Thomas Powles, Zoe June Assaf, Viraj Degaonkar, et al. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. Eur Urol 2024;85:114–22
European Urology ( IF 25.3 ) Pub Date : 2024-04-21 , DOI: 10.1016/j.eururo.2024.03.040 Viria Beccia 1 , Giada Pinterpe 2 , Roberto Iacovelli 3
中文翻译：
回复：Thomas Powles、Zoe June Assaf、Viraj Degaonkar 等人。根据 IMvigor010 3 期试验的循环肿瘤 DNA 状态更新总体生存率：Atezolizumab 辅助治疗与肌层浸润性尿路上皮癌观察。欧洲尿毒症 2024 年；85:114–22
更新日期：2024-04-21
European Urology ( IF 25.3 ) Pub Date : 2024-04-21 , DOI: 10.1016/j.eururo.2024.03.040 Viria Beccia 1 , Giada Pinterpe 2 , Roberto Iacovelli 3
Affiliation
中文翻译：
回复：Thomas Powles、Zoe June Assaf、Viraj Degaonkar 等人。根据 IMvigor010 3 期试验的循环肿瘤 DNA 状态更新总体生存率：Atezolizumab 辅助治疗与肌层浸润性尿路上皮癌观察。欧洲尿毒症 2024 年；85:114–22
京公网安备 11010802027423号